Cargando…
Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis
BACKGROUND: Retinal vein occlusion (RVO) is a common retinal venous disorder that causes vision loss. No specific therapy has been developed. Controversy exists regarding two treatments: intravitreal dexamethasone implants and anti-vascular endothelial growth factor (VEGF). The goal of this study is...
Autores principales: | Gao, Lixiong, Zhou, Lijun, Tian, Chunyu, Li, Na, Shao, Weiyang, Peng, Xiujun, Shi, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325672/ https://www.ncbi.nlm.nih.gov/pubmed/30621640 http://dx.doi.org/10.1186/s12886-018-1016-7 |
Ejemplares similares
-
Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
por: Nghiem-Buffet, S, et al.
Publicado: (2017) -
Comparison of Intravitreal Dexamethasone Implant and Intravitreal Ranibizumab Efficacy in Younger Patients with Branch Retinal Vein Occlusion
por: Ozcift, Seda Gurakar, et al.
Publicado: (2023) -
Commentary on “Intravitreal dexamethasone implant for management of treatment-naïve retinal vein occlusion”
por: Bansal, Mayank
Publicado: (2018) -
Impact of Intravitreal Dexamethasone Implant on Vessel Diameters in Patients with Retinal Vein Occlusion
por: Yilmaz Tugan, Busra, et al.
Publicado: (2019) -
Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema
por: Choi, Eun Young, et al.
Publicado: (2019)